CCDC25 and breast carcinoma: Clinically, in our cohort of patients with breast cancer receiving NAC, high tumoral expression of CCDC25 was correlated with reduced long-term survival (Figure 6, A–C), and this was corroborated by 2 online databases (45, 55) (Supplemental Figure 10, A and B).